Ascendiant Capital maintains Aemetis at Buy, lowers price target to $18 from $20

Ascendiant Capital retained its Buy rating for Aemetis but reduced its price target from $20 to $18, a 10% cut. The new target suggests a 1400% upside from the Nov 13 close of $1.20, according to the firm.

Original reporting
Published Nov 16, 2026, 11:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ascendiant Capital maintains Aemetis at Buy, lowers price target to $18 from $20 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade may trigger short-term selling but long-term fundamentals remain unchanged.

02

Market read

Analyst price target adjustment provides a modest trading signal for Aemetis shareholders.

03

What to watch

Potential upcoming contracts or policy incentives for biofuels not reflected in the rating.

Relevance 5/10Novelty 5/10Timing: today

Background

Aemetis is a small-cap renewable fuels company; analyst rating changes are a common catalyst for price movement.

Market effects

Minor impact on renewable energy sector sentiment.

Limited to US small-cap investors.

Low

Counterpoint

Some investors may view the target cut as an entry point if they believe the market overreacts.

Key entities

  • Ascendiant Capital

    Equity research firm providing the rating update.

  • Aemetis Inc.

    Renewable fuels producer.

Related articles

$AMTXMed

Aemetis Reports Third Quarter 2026 Financial Results

AEMETIS, INC (AMTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aemetis Reports Third Quarter 2026 Financial Results Net Income of $5.2 million, Revenue Growth of 49%, Adjusted EBITDA of $24.8 million • Revenues of $88.2 million, an increase of $29.0 million (49%) over the third quarter of 2025 • Aemetis Biogas RNG sales volume g

$AMTXMedAI 8/10

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) reported Q2 2026 revenue of $62.7M, up 20% YoY, with operating income of $5.8M, reversing a prior-year loss. Growth was driven by ethanol and renewable natural gas segments. Adjusted EBITDA improved to $9.7M from -$5.8M. Management highlighted projects like mechanical vapor recompression and LCFS pathway approvals, but noted risks from uncertain emissions rates and feedstock constraints.

$AMTXMed

Aemetis (AMTX) Q2 2026 Earnings Call Transcript

Aemetis (AMTX) Q2 2026 earnings call said consolidated revenue rose 20% year over year, operating income improved by $16.4 million, and adjusted EBITDA increased by $15.5 million versus Q2 2025. The company cited CARB approval of 7 LCFS pathways and pending approvals for 6 digesters, plus ethanol projects including a $32 million annual cash flow MVR system. India biodiesel revenue was $2.5 million, with expected $17 million from new allocations.

$AMTXMed

Aemetis Q2 2026 Earnings: Financial Results, Revenue, and Segment Performance Highlights – Minichart

Aemetis reported Q2 2026 revenue of $62.7 million, up $10.5 million (20%) from Q2 2025, including $8.6 million from Section 45Z tax credits. Operating income improved by $16.4 million, net loss narrowed to $9.4 million, and adjusted EBITDA rose to $9.7 million. The company is pursuing refinancing and financing for its Keyes ethanol and Dairy RNG projects, and is considering an IPO for its India unit.